Gene Therapy Center Austria (GTCA) | Takeda

4:45 PM - 5:00 PM (JST), Tuesday, March 5, 2019 ・ 2nd Floor
Cost-effective solutions for cGMP manufacturing of high quality AAV based Gene Therapy Products

More than 400 gene therapy products are currently in clinical development. The adeno-associated virus (AAV) is increasingly used for gene delivery. Manufacturing of gene therapy products is characterized by high process complexity and low yield. Over the last years various teams have been successfully working on process improvements. Today industry efforts are no longer focusing on technical issues but on reproducibility, compliance and cost of goods. The Gene Therapy Center Austria developed a scalable and robust AAV platform process applicable for different (all) AAVs and capable of delivering high quality AAV gene therapy products at low cost of goods. The Gene Therapy Center Austria progresses gene therapy products seamlessly to commercial manufacturing performing all steps from inoculum to filling at one site.
Ticker:
LSE
Exchange:
GBP
Company Type:
Company Website:
Company HQ State:
Not Provided
Company HQ Country:
Austria
Year Founded:
Not Provided
Main Therapeutic Focus:
Lead Product in Development:
Hemophilia A Gene Therapy
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided